GES Newsletter June 2023
GES Newsletter June 2023
In June, GES had a focussed month as begin our expansion and product development for new offerings later this year and in 2024. To date, we now offer a variety of Active Pharmaceutical Ingredients (APIs) unique based on the selection of chemovar used to manufacture the APIs. These APIs have been anecdotally categorized based on our client feedback into chemovar varietals for pain, anxiety, appetite, insomnia, and a few others based on our scientific profiling and data collection of these varietals.
Our unique single chemovar offerings include:
These 10+ unique chemovars form the baseline for our current products and our future expansion products that we are now developing to offer to our clients.
The first product we have stability on and going that has a scientifically formulated baseline using these unique chemovars are our Pre-Filled Inhalation Cartridges .
These include a chemovar-specific formulation derived from a single source that has been manufactured to enhance the therapeutic potential of the derived chemovar it has been manufactured for. These chemovars include:
We are pleased that these products have 12+ months of stability now in the marketplace and we continue to innovate in our formulation of these.
We are excited to also announce a mini-expansion phase for GES at our current facility, whereby over the next 6-12 months we will be adding more manufacturing cleanrooms and capabilities supporting our baseline API group. As part of our expansion, we will be moving towards offering Formulated Extracts and Generic Formulations .
Our Formulated extracts will be formulated using the baseline APIs used in our inhalation cartridges at various THC and CBD ratios blended with MCT, bottled in a 30ml bottle fitted with a 1ml dosing syringe.
As part of our growth into the pharmaceutical medicines space, we will be expanding to offer a generic formulation that will be supplied in 200ml bottles, supplied with a traditional identification pharmacy kit.
Please visit our website to find out more about our current offerings and expanded offerings in the future.
International Travels
领英推荐
In the months of June, July, and August our directors traveled and will be traveling to Germany and Australia.
In June, our Commercial Director, Gustav, visited the ICBC Berlin conference on June 29 where we met up with our partners from all around the world. This event provided an opportunity for us to connect with industry leaders and discuss our current offerings and future plans with the business goals.
From 20 July to the 15th August our Managing Director, Peter, and Commercial Director, Gustav, will be spending 3 weeks in Australia. They will initially be heading to Perth from the 20th of July to the 25th then spending time in Melbourne from the 26th of July to the 3rd of August. Next, they will spend some time in Sydney until making their way up to Brisbane on the 10th of August to visit the UIC conference and connect with partners and industry leaders.
If you are in Australia and would like to connect - please do reach out.
From July to August, our production Director, James, will be traveling to various parts of Germany to discuss with our current equipment suppliers our expansion plans as well as meet new technology manufacturers to identify any new technologies that have been useful.
Our experience with German engineering companies and technologies has been extremely supportive of our company's growth and we look forward to sharing awesome photos of the places we visited and see and the types of technologies possible for the cannabis industry in novel ways.
GES Growth
In June we initiated a mini-growth phase for our business that will take 12 months to complete before bringing it online. Since 2020, we have been growing organically with our clients and we continue to reinvest in the business through our partnerships to continue growth for our clients offering.
After deploying research and development strategies, we can conclude that we will be expanding organically over the next 12 months into the following categories:
This growth for our business brings us closer to becoming a medium-sized pharmaceutical manufacturer.
Laboratory Principal Analyst at PetroSA
1 年very impressive.... need to secure a laboratory position to make a contribution to the growth of this amazing group. ??